Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204 Life Science Investing
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug in Atopic Dermatitis Life Science Investing
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants Life Science Investing
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting Life Science Investing
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Life Science Investing
PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements Life Science Investing
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors Life Science Investing
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates Life Science Investing
